drugset / Trial / NCT02945020
A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to evaluate the effect of steady-state concentrations of odalasvir (ODV), as a single agent or in combination with simeprevir (SMV), on the single-dose pharmacokinetics of dabigatran etexilate in healthy participants.
Timeline
- Start
- 2016-11-10
- Primary completion
- 2017-01-09
- Completion
- 2017-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 75 mg | Oral |
| Subject | Odalasvir | Small molecule | 25 mg | Oral |
| Subject | Simeprevir | Small molecule | 75 mg | Oral |
Indications
No indication recorded.